Clinical trials: Normal Lungs
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen.
- Conditions
- Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
- Trial name
- NCT02489903
- Testing
- RRx-001, Cisplatin, Etoposide
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- EpicentRx, Inc.
Small Cell Lung Cancer (SCLC), Neuroendocrine Tumors
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors.
- Trial name
- NCT01719861
- Testing
- Desipramine HCL
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Joel Neal
Systemic Sclerosis, Shortness of Breath
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis.
- Conditions
- Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
- Trial name
- NCT01051960
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles